ATBECHDEDKESFRGBGRITLILUNLSEMCPTIE......FI..........................................................*EPregister to ST.36 EBD process v 1.0 kbaumeister@epo.org (15 Jan 2013)0842173A119980520EP96926370.01996071919971216enenen1995001506019950722GB1998052019982119980520199821

A61K 31/ 00 A I

A61K 31/ 40 A I

A61K 31/ 403 A I

A61K 31/ 404 A I

A61P 25/ 06 A I

C07D 413/ 06 A I

en4-[3-(TRANS-3-DIMETHYLAMINOCYCLOBUTYL)-1H-INDOL-5-YLMETHYL]-4(S)OXAZOLIDIN-2-ONE MONOBENZOATE AND SULPHATE SALTfr4-[3-(TRANS-3-DIMETHYLAMINOCYCLOBUTYL)-1H-INDOL-5-YLMETHYL]-4(S)OXAZOLIDINE-2-ONE MONOBENZOATE ET SEL DE SULFATEde4-[3-(TRANS-3-DIMETHYLAMINOCYCLOBUTYL)-1H-INDOL-5-YLMETHYL]-4(S)OXAZOLIDIN-2-ON MONOBENZOAT UND SULFAT SALZGLAXO GROUP LIMITEDGlaxo Wellcome House, Berkeley AvenueGreenford, Middlesex UB6 0NNGBSELWOOD, David, Lawrence6 Birchall Wood, Welwyn Garden CityHertfordshire AL7 2HLGBBROCKWELL, Michael, JohnLangley Court, South Eden Park RoadBeckenham, Kent BR3 3BSGBHesketh, Alan, et alGlaxo Wellcome plc Glaxo Wellcome House, Berkeley AvenueGreenford, Middlesex UB6 0NNGBATBECHDEDKESFIFRGBGRIEITLILUMCNLPTSEEP199600318819960719enWO199700398319970206199707